lenalidomide has been researched along with Kidney Failure in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (12.82) | 29.6817 |
| 2010's | 32 (82.05) | 24.3611 |
| 2020's | 2 (5.13) | 2.80 |
| Authors | Studies |
|---|---|
| Ikeda, N; Kakimoto, T; Kusunoki, Y; Namba-Hamano, T; Takeji, M; Teramoto, K; Wakabayashi, K; Yamamoto, S | 1 |
| Cao, Y; Chen, CI; Chen, E; Chen, H; Kakar, S; Kukreti, V; Lau, A; Le, LW; Levina, O; Paul, H; Prica, A; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Catalano, L; Cerchione, C; Martinelli, V; Nappi, D; Pane, F; Pareto, AE; Picardi, M; Romano, A | 1 |
| Aldaoud, A; Harde, J; Knauf, W; Losem, C; Mittermueller, J; Neise, M; Niemeier, B; Potthoff, K; Trarbach, T | 1 |
| Harada-Shirado, K; Hashimoto, Y; Ikeda, K; Ikezoe, T; Kazama, JJ; Kimura, S; Matsumoto, H; Ogawa, K; Ohkawara, H; Sano, T; Shichishima-Nakamura, A; Takahashi, H; Tanaka, M; Ueda, K | 1 |
| Tomlinson, R | 1 |
| Dueck, AC; Hayman, S; Kanate, AS; Lonial, S; Manola, J; Mikhael, J; Oettel, K; Rajkumar, SV | 1 |
| Fujimoto, T; Koyama, A; Kurihara, T; Nishikawa, A; Okamoto, Y; Shiotani, C; Tamura, S | 1 |
| Ai, H; Cai, Z; Chen, F; Chen, N; DeMarco, D; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wang, J; Wu, D; Yu, L; Zhang, J; Zhou, DB | 1 |
| Cejalvo, MJ; de la Rubia, J | 1 |
| Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R | 1 |
| Izzedine, H; Kheder El-Fekih, R | 1 |
| Coelho, I; Esteves, GV; Esteves, S; Freitas, J; Geraldes, C; Gomes, F; João, C; Lúcio, P; Neves, M | 1 |
| Hagihara, M; Hua, J; Inoue, M; Uchida, T | 1 |
| Abraham, J; Arnulf, B; Bridoux, F; Chen, N; Desport, E; Fermand, JP; Jaccard, A; Moreau, S; Moumas, E | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Terpos, E | 1 |
| Dimopoulos, MA; Kastritis, E; Rajkumar, SV | 1 |
| Bladé, J; Dimopoulos, MA; Kastritis, E; Ludwig, H; Rosinol, L | 1 |
| Borrello, I | 1 |
| Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Grapsa, I; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Ludwig, H; Zojer, N | 1 |
| Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gika, D; Grapsa, I; Kastritis, E; Migkou, M; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Alegre, A; de Castro, CM; Dimopoulos, M; Goldschmidt, H; Masliak, Z; Olesnyckyj, M; Reece, D; Stadtmauer, EA; Weber, DM; Yu, Z; Zonder, JA | 1 |
| Dember, LM; Fennessey, S; Finn, KT; Sanchorawala, V; Seldin, DC; Shelton, A; Specter, R; Zeldis, JB | 1 |
| Goldschmidt, H; Heiss, C; Hielscher, T; Ho, AD; Klein, U; Neben, K | 1 |
| Anderson, K; Laubach, J; Richardson, P | 1 |
| González Rodríguez, AP | 1 |
| Fenaux, P; Freeman, J; Palumbo, A; Weiss, L | 1 |
| Dimopoulos, MA; Eleftherakis-Papapiakovou, E; Gkotzamanidou, M; Grapsa, I; Kastritis, E; Nikitas, N; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Anderson, KC; Gaballa, MR; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Munshi, N; Noonan, K; Redman, K; Richardson, PG; Schlossman, RL | 1 |
| Chanan-Khan, AA; Dimopoulos, MA; Jagannath, S; Ludwig, H; San Miguel, JF | 1 |
| Hahn-Ast, C; Kuhn, S; Langer, C; Oehrlein, K; Pönisch, W; Sturm, I; Weisel, KC | 1 |
| Mizutani, M; Ohya, E; Sekine, T | 1 |
| Alegre, A; Dimopoulos, MA; Goldschmidt, H; Mark, T; Niesvizky, R; Terpos, E | 1 |
| Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E | 1 |
| Suzuki, K | 1 |
| Chen-Kiang, S; Christos, PJ; Coleman, M; Ely, S; Furst, JR; Jalbrzikowski, J; Jayabalan, D; Lent, R; Leonard, JP; Mark, T; Mazumdar, M; Naib, T; Niesvizky, R; Pearse, RN; Zafar, F | 1 |
| Gertz, MA | 1 |
13 review(s) available for lenalidomide and Kidney Failure
| Article | Year |
|---|---|
Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Renal Insufficiency; Risk Factors; Stem Cell Transplantation; Thalidomide | 2015 |
[Lenalidomide nephrotoxicity].
Topics: Graft vs Host Disease; Humans; Immunologic Factors; Kidney; Kidney Tubules; Lenalidomide; Necrosis; Nephritis, Interstitial; Prevalence; Renal Insufficiency; Thalidomide | 2016 |
Current treatments for renal failure due to multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Renal Insufficiency; Thalidomide | 2016 |
Treatment of plasma cell dyscrasias with lenalidomide.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Pyrazines; Renal Insufficiency; Thalidomide; Thromboembolism; Waldenstrom Macroglobulinemia | 2008 |
Pathogenesis and treatment of renal failure in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2008 |
Multiple myeloma.
Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Management of the adverse effects of lenalidomide in multiple myeloma.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Humans; Infections; Lenalidomide; Multiple Myeloma; Neutropenia; Practice Guidelines as Topic; Renal Insufficiency; Thalidomide; Thrombocytopenia; Treatment Outcome; Venous Thromboembolism | 2011 |
The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Topics: Administration, Oral; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Product Surveillance, Postmarketing; Renal Insufficiency; Thalidomide; Time Factors | 2012 |
Management of myeloma-associated renal dysfunction in the era of novel therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prednisone; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide; Treatment Outcome | 2012 |
Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Prospective Studies; Renal Insufficiency; Retrospective Studies; Thalidomide | 2012 |
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
Current therapy of myeloma induced renal failure.
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2008 |
6 trial(s) available for lenalidomide and Kidney Failure
| Article | Year |
|---|---|
Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Drug Monitoring; Female; Humans; Kidney Function Tests; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Renal Insufficiency; Survival Analysis; Treatment Outcome | 2018 |
Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; China; Dexamethasone; Disease-Free Survival; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Renal Insufficiency; Thalidomide | 2015 |
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Renal Insufficiency; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Creatinine; Dexamethasone; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Kidney Function Tests; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Recurrence; Renal Insufficiency; Thalidomide | 2016 |
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Renal Insufficiency; Thalidomide | 2010 |
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neutropenia; Renal Insufficiency; Thalidomide; Thrombocytopenia; Treatment Outcome | 2007 |
20 other study(ies) available for lenalidomide and Kidney Failure
| Article | Year |
|---|---|
A case of proliferative glomerulonephritis with immunoglobulin A1-lambda deposits successfully treated by chemotherapy.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow; Dexamethasone; Glomerulonephritis, Membranoproliferative; Humans; Immunoglobulin A; Immunoglobulin lambda-Chains; Immunohistochemistry; Immunologic Factors; Lenalidomide; Male; Microscopy, Electron; Multiple Myeloma; Nephrotic Syndrome; Paraproteinemias; Renal Insufficiency; Treatment Outcome | 2020 |
An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Renal Insufficiency; Thalidomide; Treatment Outcome | 2020 |
[Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma].
Topics: Consensus; Creatinine; Dexamethasone; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Multiple Myeloma; Renal Dialysis; Renal Insufficiency; Renal Insufficiency, Chronic; Thalidomide | 2017 |
Lenalidomide at the dose of 25 mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience.
Topics: Aged; Aged, 80 and over; Female; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Renal Insufficiency; Retrospective Studies | 2018 |
Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Disease Progression; Febrile Neutropenia; Female; Humans; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Insufficiency; Thrombosis | 2018 |
Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease.
Topics: Aged; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Male; Paraproteinemias; Proteinuria; Renal Insufficiency | 2018 |
Multiple myeloma: Updated approach to management in 2018.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Bortezomib; Disease Management; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Pain; Prognosis; Renal Insufficiency; Serum Albumin; Thalidomide | 2018 |
Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Hypertension, Pulmonary; Induction Chemotherapy; Lenalidomide; Leukemia, Plasma Cell; Male; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide | 2014 |
Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
Topics: Aged; Aged, 80 and over; Cohort Studies; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Renal Insufficiency; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2016 |
Achievement of hemodialysis discontinuation with lenalidomide and dexamethasone therapy in a refractory BJP-type multiple myeloma patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Dialysis; Renal Insufficiency; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide in renal insufficiency--balancing the risks and benefits.
Topics: Antineoplastic Agents; Area Under Curve; Humans; Lenalidomide; Multiple Myeloma; Renal Insufficiency; Risk; Thalidomide; Treatment Outcome | 2009 |
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Creatinine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Kidney; Lenalidomide; Male; Methotrexate; Middle Aged; Multiple Myeloma; Renal Insufficiency; Thalidomide | 2010 |
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kidney; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide; Time Factors; Treatment Outcome; X-Rays | 2010 |
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2010 |
Kidney dysfunction during lenalidomide treatment for AL amyloidosis.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Female; Humans; Kidney Function Tests; Lenalidomide; Male; Middle Aged; Prospective Studies; Renal Insufficiency; Survival Rate; Thalidomide; Treatment Outcome | 2011 |
Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Disease Progression; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Insufficiency; Retrospective Studies; Thalidomide; Treatment Outcome | 2011 |
Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Renal Insufficiency; Retrospective Studies; Thalidomide; Treatment Outcome | 2012 |
[Case report: Reversible posterior leukoencephalopathy associated with the treatment of multiple myeloma: a case report].
Topics: Antineoplastic Agents; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Posterior Leukoencephalopathy Syndrome; Renal Insufficiency; Thalidomide | 2012 |
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Renal Insufficiency; Survival Rate; Thalidomide; Vincristine | 2013 |